Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Citius Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CTXR
Nasdaq
8731
https://www.citiuspharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Citius Pharmaceuticals Inc
Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company
- Mar 30th, 2023 12:30 pm
When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven?
- Mar 27th, 2023 1:52 pm
Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank
- Mar 13th, 2023 1:15 pm
Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference
- Mar 8th, 2023 1:30 pm
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update
- Feb 10th, 2023 9:30 pm
Here Are 2 Ways I'm Playing the Market With Small-Cap Stocks
- Feb 6th, 2023 3:30 pm
Sidoti's January Micro-Cap Conference
- Jan 17th, 2023 3:00 pm
Here's Why We're Not Too Worried About Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation
- Jan 16th, 2023 12:09 pm
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023
- Jan 11th, 2023 1:30 pm
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)
- Dec 28th, 2022 2:35 pm
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update
- Dec 22nd, 2022 9:30 pm
Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
- Dec 1st, 2022 12:30 pm
Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program
- Nov 21st, 2022 1:00 pm
Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting
- Nov 9th, 2022 1:30 pm
Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022
- Oct 18th, 2022 12:30 pm
Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Profit Outlook
- Oct 18th, 2022 11:59 am
Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022
- Oct 6th, 2022 8:30 pm
Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
- Sep 28th, 2022 12:30 pm
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings
- Sep 23rd, 2022 10:48 am
Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-Initiated Trial
- Sep 22nd, 2022 8:30 pm
Scroll